The use of sirolimus as a rescue therapy in pediatric intestinal transplant recipients
Article first published online: 11 OCT 2010
© 2010 John Wiley & Sons A/S
Volume 14, Issue 7, pages 931–935, November 2010
How to Cite
Andres, A. M., Lopez Santamaría, M., Ramos, E., Hernandez, F., Prieto, G., Encinas, J., Leal, N., Molina, M., Sarría, J. and Tovar, J. (2010), The use of sirolimus as a rescue therapy in pediatric intestinal transplant recipients. Pediatric Transplantation, 14: 931–935. doi: 10.1111/j.1399-3046.2010.01363.x
- Issue published online: 15 OCT 2010
- Article first published online: 11 OCT 2010
- Accepted for publication 14 April 2010
- intestinal transplantation;
Andres AM, Lopez Santamaría M, Ramos E, Hernandez F, Prieto G, Encinas J, Leal N, Molina M, Sarría J, Tovar JA. The use of sirolimus as a rescue therapy in pediatric intestinal transplant recipients. Pediatr Transplantation 2010: 14: 931–935. © 2010 John Wiley & Sons A/S.
Abstract: To review our experience with SRL as a second-line therapy in our series of 45 SBTx recipients (1997–2009). Retrospective review of five children converted to SRL: 3 M/2 F; median of three yr old (range 20 months–18 yr); rescue indications, adverse events with SRL, resolution of tacrolimus-related side effects, incidence of rejection, PTLD, or GVHD were summarized. Tacrolimus was discontinued (average 13 months after transplant) because of refractory hemolytic anemia in four patients with decreased renal function and because of advanced renal failure and unclear neutropenia in one. PTLD and GVHD had been previously diagnosed in two. Tacrolimus-related side effects disappeared in all five although other immunosuppressants and splenectomy were used simultaneously or later in most of them. Adverse events reported after the conversion were infections (tuberculosis and Pneumocystis carinii in two) and mild hypertriglyceridemia. No rejection, GVHD, or PTLD episode was observed. Four patients are alive with excellent quality of life (median follow-up 18 months). Sirolimus is a safe rescue therapy in SBTx children when tacrolimus is not well tolerated. Renal function and hematologic disorders seem to improve, although other simultaneous strategies could be also involved. Further studies could demonstrate its efficacy as a first-line treatment.